SCHEMBL5776791

SCHEMBL5776791

c1cc2c(cc1CNc1nc(N3CCOCC3)nc3sc4c(c13)CCCC4)OCO2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.48
TSHR P16473 4/20 0.47
KDM4E B2RXH2 4/20 0.47
GAA P10253 3/20 0.47
HSD17B10 Q99714 2/20 0.47
MAPT P10636 3/20 0.46
HTT P42858 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PTPN12 Q05209 1/20 0.46
PTPN22 Q9Y2R2 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
TP53 P04637 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
GALR2 O43603 1/20 0.44
PDE4A P27815 2/20 0.43
PDE4B Q07343 2/20 0.43
PDE4C Q08493 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5776894 0.87 ALDH1A1 (0.49) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL7015609 0.86 PDE4A (0.62) ALDH1A1TSHRKDM4EGAAHSD17B10
SCHEMBL8180369 0.86 ALDH1A1 (0.49) ALDH1A1TSHRKDM4EGAAHSD17B10
SCHEMBL8171969 0.84 PDE4A (0.51) ALDH1A1TSHRKDM4EGAAHSD17B10
SCHEMBL7015052 0.84 PDE4A (0.50) ALDH1A1TSHRKDM4EGAAHSD17B10
SCHEMBL5116989 0.84 ALDH1A1 (0.47) ALDH1A1TSHRKDM4EGAAHSD17B10
SCHEMBL5798039 0.83 PTPN12 (0.47) ALDH1A1MAPTHTTMEN1KMT2A
SCHEMBL8179966 0.82 PDE4A (0.56) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL5777372 0.82 PTPN12 (0.45) ALDH1A1TSHRKDM4EGAAHSD17B10
SCHEMBL5777790 0.82 PTPN12 (0.45) ALDH1A1TSHRKDM4EGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1685136-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 2006-08-02 EP claimed
WO-2005047292-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 2005-05-26 WO claimed
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
EP-1685136-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 2006-08-02 EP disclosed
WO-2005047292-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 2005-05-26 WO disclosed
WO-2005047292-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 2005-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 ALDH1A1 1055/4885TSHR 1050/4885KDM4E 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.